Type 2 hereditary angioedema treated with acute exacerbation with icatibant: A case report
Allergy, Asthma & Respiratory Disease
; : 180-183, 2021.
Article
in En
| WPRIM
| ID: wpr-913308
Responsible library:
WPRO
ABSTRACT
Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by genetic deficiency or decreased function of C1-esterase inhibitor. It is characterized by swelling of subcutaneous and submucosal tissues of the extremities, gastrointestinal tract, and upper airways which can be life-threatening. Thus, early recognition and treatment of the disease are important. Short- and longterm prophylaxes are used to decrease the severity and frequency of attacks. Icatibant is a selective bradykinin B2-receptor antagonist, earlier treatment of acute attacks and hospital admission. The authors present a case of 47-year-old woman who was diagnosed with type II HAE, danazol as a long term. Her symptoms improved dramatically after drug treatment. The unpredictability and recurrence of HAE attacks could have a negative impact on social life and quality of life. This case shows that timely and proper treatment could improve quality of life and reduce morbidity and mortality. (
Full text:
1
Index:
WPRIM
Language:
En
Journal:
Allergy, Asthma & Respiratory Disease
Year:
2021
Type:
Article